«Type-2 diabetes affects 390 million people worldwide resulting in almost 5 million deaths from diabetes annually.»
Type-2 diabetes affects 390 million people worldwide resulting in almost 5 million deaths annually. The prevalence of diabetes is increasing dramatically in both developed and developing countries due to population growth, aging, urbanization, and increasing prevalence of obesity and physical inactivity. Current treatments include dietary management and pharmacological intervention acting on different pathways to decrease blood glucose levels by either improving insulin sensitivity or stimulating the pancreas to release insulin.
Neurimmune’s program for the treatment of type-2 diabetes identified unique recombinant human-derived antibodies targeting toxic aggregates of islet amyloid polypeptide that cause dysfunction and degeneration of insulin-producing pancreatic beta cells. The selected lead candidate demonstrated strong in vivo proof-of-concept in independent disease models and species resulting in improved beta-cell function, increased insulin secretion and content, improved glucose tolerance, reduced fasting glucose and normalized body weight gain.